Gene-Edited iNKT Cell Expressing Chimeric Antigen Receptor for the Treatment of Cancer

by | Mar 6, 2025 | Cooper, Matthew, DiPersio, John

— Value Proposition: Engineered iNKT cells with potential as a “universal” source of immune effector cells to treat cancer.

Technology Description

Researchers at Washington University in St. Louis have developed a new composition of matter that uses gene-edited invariant natural kill…

PI3K inhibitors to treat Cytokine Release Syndrome

by | Jan 15, 2021 | Amatya, Parmeshwar, Carter, Alun, Cooper, Matthew, DiPersio, John

— Technology Description

A team of researchers, led by John DiPersio and Matthew Cooper at Washington University in St. Louis, have identified a small molecule kinase inhibitor capable of mitigating cytokine release syndrome following CAR-T cell therapy. PI3K inhibitors can suppress production of IL-…

Your Collections

Name	# Summaries	Author
Cardiovascular	15	peek
COVID-19	13	peek
Immuno-Oncology	15	peek
Oncology	26	peek
PET Tracers	14	peek
Radiology	14	peek

Create a Collection

Creating...

WASHU INNOVATION CATALOG

Gene-Edited iNKT Cell Expressing Chimeric Antigen Receptor for the Treatment of Cancer

PI3K inhibitors to treat Cytokine Release Syndrome

Your Collections

Office of Technology Management